Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8 PF-07321332 Boceprevir Entèmedyè
Pwovizyon Komèsyal PF-07321332 Paxlovid ki gen rapò ak Entèmedyè ak kalite siperyè
L-tèt-Leucine (H-Tle-OH) CAS 20859-02-3
Karonic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic asid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Non Chimik | Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate |
Sinonim | Methyl (S)-2-((tèt-butoxicarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate;(αS,3S)-α-[(tèt-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic asid Methyl Ester;(S)-Methyl 2-((tèt-butoxicarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate |
Nimewo CAS | 328086-60-8 |
Nimewo CAT | RF-PI317 |
Estati Stock | Nan stock, pwodiksyon echèl jiska dè santèn de kilogram |
Fòmil molekilè | C13H22N2O5 |
Pwa molekilè | 286.33 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Poud blan pou blan |
Idantifikasyon A | IR: Menm jan ak sibstans referans |
Idantifikasyon B | Tan Retansyon: Menm jan ak Sibstans Referans |
Pèt sou siye | ≤1.0% |
Rezid sou ignisyon | ≤0.20% |
Single enpurte | ≤0.50% |
Enpurte total | ≤2.0% |
Metal lou (Pb) | ≤20ppm |
Pite | ≥98.0% |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan PF-07321332 Paxlovid (CAS 2628280-40-8) ak Boceprevir (CAS 394730-60-0) |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate (CAS 328086-60-8) se entèmedyè PF-07321332 Paxlovid (CAS 2628280-40). -8) ak Boceprevir (CAS 394730-60-0).PF-07321332, eleman kle nan Paxlovid (PF-07321332 ak Ritonavir) ki se yon ankèt COVID-19 kandida antiviral oral, se yon inibitè 3C-tankou proteaz (3CLPRO) ki gen yon efè antiviral ki pisan kont viris SARS-CoV-2. ak COVID-19.6 Novanm 2021, Pfizer te anonse ke Paxlovid te redwi anpil entène lopital ak lanmò, dapre yon analiz pwovizwa EPIC-HR Faz 2/3 (Evalyasyon anpèchman pwoteaz pou COVID-19 nan pasyan ki gen gwo risk) etid owaza, doub avèg. pasyan adilt ki pa entène lopital ak COVID-19, ki gen gwo risk pou yo pwogrese nan maladi grav.Boceprevir (EBP-520) se yon inibitè proteaz HCV (Ki = 14 nM) pou tretman enfeksyon viris epatit C.Boceprevir ak interferon pegylated ak ribavirin (PegIFN/RBV) te pèmèt amelyorasyon nan pousantaj repons virolojik soutni pasyan ki gen jenotip 1 HCV.Boceprevir reyaji ak terapi imunosuppressive (IT) lè li anpeche anzim cytochrome P450 3A a.